The following biotech stocks touched a new 52-week high yesterday.
AVEO Pharmaceuticals Inc. (AVEO) is just one step away from getting a U.S. patent for the use of its lead product Fotivda for the treatment of refractory advanced renal cell carcinoma. Shares touched a 52-week intraday high of $9.62 yesterday.
Yesterday, the company announced that the United States Patent and Trademark Office ("USPTO") has allowed U.S. Patent Application No. 17/720,619, titled "Use of Tivozanib to Treat Subjects with Refractory Cancer". This Application will potentially issue as a patent in 2022 and will provide patent protection in the United States for the claimed methods of use of FOTIVDA into 2039.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.